Literature DB >> 20533029

The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders.

D L Kelly1, C S Myers, M T Abrams, S Feldman, J Park, R P McMahon, J-C Shim.   

Abstract

UNLABELLED: Review of the 1-year prevalence of screening for osteoporosis and of osteoporosis or idiopathic fracture in Maryland Medicaid administrative records found that screening rates did not differ among women in the control population, women with psychosis, and women with major mood disorders, but were reduced compared to controls in women with substance use disorder, with or without psychosis. Prevalence of osteoporosis was increased compared to controls in women with major mood disorders or women over 55 dually diagnosed with psychosis and substance use disorder.
INTRODUCTION: Osteoporosis is a major public health concern. Substance abuse and psychosis may be risk factors, however, frequency of screening and disease risk in women with psychotic disorders and substance use disorder (SUD) remains unknown.
METHODS: This study examined rates (FY 2005) of osteoporosis screening and disease risk in Medicaid enrolled women aged 50 to 64 (N = 18,953). Four diagnostic groups were characterized: (1) psychosis, (2) SUD, (3) major mood disorder, and (4) controls. The interaction of psychosis and SUD on screening and disease prevalence of osteoporosis was tested.
RESULTS: The prevalence of osteoporosis across the entire population was 6.7%. Four percent of those without an osteoporosis diagnosis received osteoporosis screening with no notable differences between psychosis and controls. Those with SUD, however, had a significant reduction in screening compared to controls (OR = 0.61, 95% CI = 0.40-0.91, p = 0.016). Women with a major mood disorder were more likely to have osteoporosis in their administrative record (OR = 1.32, 95% CI = 1.03-1.70, p = 0.028) compared to controls. Those who were dually diagnosed (SUD and psychosis) in the oldest ages (55-64 years) had a markedly higher prevalence of osteoporosis compared to controls (OR = 6.4 CI = 1.51-27.6, p = 0.012), whereas this interaction (SUD and psychosis) was not significant in the entire population over age 49.
CONCLUSIONS: Osteoporosis screening in the Medicaid population is significantly lower for women with SUD, after adjusting for age, race, and Medicaid enrollment category. The prevalence of osteoporosis appears markedly elevated in those with major mood disorders and those over age 55 dually diagnosed with schizophrenia and SUD.

Entities:  

Mesh:

Year:  2010        PMID: 20533029      PMCID: PMC3557797          DOI: 10.1007/s00198-010-1294-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  45 in total

Review 1.  Detection and management of comorbidity in patients with schizophrenia.

Authors:  Alan I Green; Carla M Canuso; Mark J Brenner; Joanne D Wojcik
Journal:  Psychiatr Clin North Am       Date:  2003-03

2.  Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys.

Authors:  Pamela K Adelmann
Journal:  Adm Policy Ment Health       Date:  2003-11

3.  Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery.

Authors:  Barbara E Havassy; Jennifer Alvidrez; Karilyn K Owen
Journal:  Am J Psychiatry       Date:  2004-01       Impact factor: 18.112

Review 4.  Osteoporosis prevention, diagnosis, and therapy.

Authors: 
Journal:  JAMA       Date:  2001-02-14       Impact factor: 56.272

5.  Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Mark Helfand; Steven H Woolf; Janet D Allan
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

6.  Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.

Authors:  Daniel Becker; Olga Liver; Roberto Mester; Micha Rapoport; Abraham Weizman; Mordechai Weiss
Journal:  J Clin Psychiatry       Date:  2003-07       Impact factor: 4.384

7.  Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study.

Authors:  Robin G McCreadie
Journal:  Br J Psychiatry       Date:  2002-10       Impact factor: 9.319

8.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

Authors:  Dana Bliuc; Nguyen D Nguyen; Vivienne E Milch; Tuan V Nguyen; John A Eisman; Jacqueline R Center
Journal:  JAMA       Date:  2009-02-04       Impact factor: 56.272

9.  Bone mass in schizophrenia and normal populations across different decades of life.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Ching-Mo Chueh; Chih-Yuan Lin; Tsuo-Hung Lan; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2009-01-01       Impact factor: 2.362

10.  Alcohol and other factors affecting osteoporosis risk in women.

Authors:  H Wayne Sampson
Journal:  Alcohol Res Health       Date:  2002
View more
  3 in total

1.  Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders.

Authors:  Michael T Abrams; Carol S Myers; Stephanie M Feldman; Cynthia Boddie-Willis; Junyong Park; Robert P McMahon; Deanna L Kelly
Journal:  Psychiatr Serv       Date:  2012-08       Impact factor: 3.084

2.  Psychiatric morbidity and cervical cancer screening: a retrospective population-based case-cohort study.

Authors:  Michael Ouk; Jodi D Edwards; Jessica Colby-Milley; Alexander Kiss; Walter Swardfager; Marcus Law
Journal:  CMAJ Open       Date:  2020-03-10

3.  Hip, vertebral, and wrist fracture risks and schizophrenia: a nationwide longitudinal study.

Authors:  Yu-Wen Chu; Wen-Pin Chen; Albert C Yang; Shih-Jen Tsai; Li-Yu Hu; Shyh-Chyang Lee; Yao-Tung Lee; Cheng-Che Shen
Journal:  BMC Psychiatry       Date:  2022-02-01       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.